Storing PT-141: Best Practices
Lyophilized Peptide Storage
Store the lyophilized powder desiccated at -20°C or below for long-term stability, protected from light and moisture. The material is supplied as a white lyophilized powder and is hygroscopic — keep tightly sealed and allow vials to reach room temperature before opening to limit condensation.
Reconstitution
Reconstitute with sterile or bacteriostatic water, directing the diluent slowly down the inside wall of the vial and swirling gently — do not shake. The reconstituted solution should appear clear and colorless.
After Reconstitution
Store the reconstituted solution refrigerated at 2°C to 8°C. Aliquot before freezing to avoid repeated freeze-thaw cycles, which degrade peptide integrity. Published stability work on this compound characterizes its degradants and epimerization behaviour by LC-HRMS/MS, underscoring the importance of controlled storage for analytical reproducibility.
Handling Precautions
Handle using standard aseptic technique with appropriate personal protective equipment. Inspect the reconstituted solution before use and do not use if it appears cloudy, discolored, or contains particulate matter. Each vial is accompanied by a Certificate of Analysis (COA) detailing purity verification via RP-HPLC and Mass Spectrometry.
“Research Summary Foundational and Mechanistic Studies StudyTypeSubject of ReportRef Molinoff et al.”
References
- Molinoff PB, Shadiack AM, Earle D, Diamond LE, Quon CY. PT-141: a melanocortin agonist for the treatment of sexual dysfunction. Ann N Y Acad Sci. 2003;994:96-102.
- Hadley ME, Dorr RT. Melanocortin peptide therapeutics: historical milestones, clinical studies and commercialization. Peptides. 2006;27(4):921-930.
- Van der Ploeg LH, Martin WJ, Howard AD, et al. A role for the melanocortin 4 receptor in sexual function. Proc Natl Acad Sci U S A. 2002;99(17):11381-11386.
- Zhang H, Chen LN, Yang D, et al. Structural insights into ligand recognition and activation of the melanocortin-4 receptor. Cell Res. 2021;31(11):1163-1175.
- Yuan XC, Tao YX. Ligands for Melanocortin Receptors: Beyond Melanocyte-Stimulating Hormones and Adrenocorticotropin. Biomolecules. 2022;12(10):1407.
- Sweeney P, Gimenez LE, Hernandez CC, Cone RD. Targeting the central melanocortin system for the treatment of metabolic disorders. Nat Rev Endocrinol. 2023;19(9):507-519.
- Giuliano F. Control of penile erection by the melanocortinergic system: experimental evidences and therapeutic perspectives. J Androl. 2004;25(5):683-691.
- Pfaus JG, Shadiack A, Van Soest T, Tse M, Molinoff P. Selective facilitation of sexual solicitation in the female rat by a melanocortin receptor agonist. Proc Natl Acad Sci U S A. 2004;101(27):10201-10204.
- Pfaus J, Giuliano F, Gelez H. Bremelanotide: an overview of preclinical CNS effects on female sexual function. J Sex Med. 2007;4 Suppl 4:269-279.
- Shadiack AM, Sharma SD, Earle DC, Spana C, Hallam TJ. Melanocortins in the treatment of male and female sexual dysfunction. Curr Top Med Chem. 2007;7(11):1137-1144.
- Shadiack AM, Althof S. Preclinical effects of melanocortins in male sexual dysfunction. Int J Impot Res. 2008;20 Suppl 1:S11-S16.
- Pfaus JG, Sadiq A, Spana C, Clayton AH. The neurobiology of bremelanotide for the treatment of hypoactive sexual desire disorder in premenopausal women. CNS Spectr. 2022;27(3):281-289.
- Dhillon S, Keam SJ. Bremelanotide: First Approval. Drugs. 2019;79(14):1599-1606.
- White WB, Myers MG, Jordan R, Lucas J. Usefulness of ambulatory blood pressure monitoring to assess the melanocortin receptor agonist bremelanotide. J Hypertens. 2017;35(4):761-768.
- Sauter M, Uhl P, Burhenne J, Haefeli WE. Ultra-sensitive quantification of the therapeutic cyclic peptide bremelanotide utilizing UHPLC-MS/MS for evaluation of its oral plasma pharmacokinetics. J Pharm Biomed Anal. 2020;186:113276.
- Yuvaraaj VK, Sharma N. Comprehensive characterization of bremelanotide acetate and its degradants by LC-HRMS/MS and predicting epimerization through computational modelling. Anal Methods. 2026.
- Mestria S, Odoardi S, Frison G, Strano Rossi S. LC-HRMS characterization of the skin pigmentation and sexual enhancers melanotan II and bremelanotide sold on the black market of performance and image enhancing drugs. Drug Test Anal. 2021;13(4):876-882.
- Suzuki S, Kitanaka C, Okada M. Melanocortin Receptor Agonist Bremelanotide Induces Cell Death and Growth Inhibition in Glioblastoma Cells via Suppression of Survivin Expression. Anticancer Res. 2024;44(9):3875-3883.
- Borland JM, Kohut-Jackson AL, Peyla AC, Hall MA, Mermelstein PG, Meisel RL. Female Syrian hamster analyses of bremelanotide, a US FDA approved drug for the treatment of female hypoactive sexual desire disorder. Neuropharmacology. 2025;267:110299.
- Merlino F, Jia L, Boccino I, et al. Goldilocks-Inspired Design of Mid-Size Macrocycles for Selective Targeting of Human Melanocortin Receptors. J Med Chem. 2026.
- Bardhan M, Anand A, Javed A, et al. Polymorphism of Melanocortin Receptor Genes-Association with Inflammatory Traits and Diseases. Diseases. 2025;13(9):305.
- Spielmans GI. Re-Analyzing Phase III Bremelanotide Trials for “Hypoactive Sexual Desire Disorder” in Women. J Sex Res. 2021;58(9):1085-1105.
- Expression of Concern: Salvage of Sildenafil Failures With Bremelanotide: A Randomized, Double-Blind, Placebo Controlled Study. J Urol. 2023 Jan 10.
- National Center for Biotechnology Information. PubChem Compound Summary for CID 9941379, Bremelanotide. PubChem. Accessed 2026-07-31.
Related Research Questions
Related research
Browse all research guides in the Peptide Research Library →Want the complete research review?
View Full PT-141 Research Page→FOR RESEARCH USE ONLY
This content is provided for educational and informational purposes only. Products are furnished for in-vitro studies only and are not medicines, drugs, or supplements. Not approved by the FDA to prevent, treat, or cure any condition.